Longitudinal Performance of Epi proColon

UnknownOBSERVATIONAL
Enrollment

4,500

Participants

Timeline

Start Date

August 18, 2017

Primary Completion Date

August 31, 2023

Study Completion Date

January 31, 2024

Conditions
Colorectal CancerColorectal Neoplasms
Interventions
DEVICE

Epi proColon

Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.

Trial Locations (6)

17822

RECRUITING

Geisinger Health System, Danville

26505

RECRUITING

West Virginia University, Morgantown

27704

RECRUITING

Duke University, Durham

48073

RECRUITING

Beaumont Health System, Royal Oak

92161

RECRUITING

Veterans Affairs San Diego Healthcare System, San Diego

08901

RECRUITING

Rutgers University Hospital, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Epigenomics, Inc

INDUSTRY

NCT03218423 - Longitudinal Performance of Epi proColon | Biotech Hunter | Biotech Hunter